Cargando…
Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey
BACKGROUND: Target-specific anticancer drugs are under rapid development. Little is known, however, about the risk of administering target-specific drugs to patients who have tumours with molecular alterations or other characteristics that can make the drug ineffective or even harmful. An increasing...
Autores principales: | Schandelmaier, Stefan, Schmitt, Andreas M, Herbrand, Amanda K, Glinz, Dominik, Ewald, Hannah, Briel, Matthias, Guyatt, Gordon H, Hemkens, Lars G, Kasenda, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264639/ https://www.ncbi.nlm.nih.gov/pubmed/32474426 http://dx.doi.org/10.1136/bmjopen-2019-034565 |
Ejemplares similares
-
Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials
por: Taji Heravi, Ala, et al.
Publicado: (2021) -
Characteristics and survival of patients with cancer with intended off-label use—a cohort study
por: Schmitt, Andreas Michael, et al.
Publicado: (2022) -
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
por: Herbrand, Amanda Katherina, et al.
Publicado: (2021) -
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
por: Herbrand, Amanda Katherina, et al.
Publicado: (2019) -
The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review
por: Sun, Xin, et al.
Publicado: (2011)